Product Center
Ab&B Bio-Tech Co., Ltd. Shines on the 2025 European International Pharmaceutical Stage
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-06
- Views:
(Summary description)From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands.
Ab&B Bio-Tech Co., Ltd. Shines on the 2025 European International Pharmaceutical Stage
(Summary description)From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-06 08:57
- Views:
From October 13th to 16th, the overseas business team of Ab&B Bio-Tech Co., Ltd. made a wonderful appearance at the World Vaccine Congress 2025 Europe held in Amsterdam, Netherlands. As the top vaccine professional event in Europe, this exhibition brings together 2500+industry elites, 280+authoritative spokespersons, and 150+participating companies from around the world, covering the entire value chain of vaccine research and development, production, and supply chain, focusing on core issues such as emerging disease vaccines.
During the exhibition, the company focused on showcasing cutting-edge innovative products such as mRNA monkeypox vaccine and quadrivalent influenza virus subunit vaccine. With diversified innovative research pipelines and mature industrialization capabilities, it attracted widespread attention from many attendees.
The team has received over 20 global clients and partners, completed more than 3 one-on-one in-depth negotiations, and successfully reached a preliminary cooperation intention covering technology licensing, joint research and development, and overseas market expansion. By actively participating in industry forums, the team has synchronized European vaccine regulatory policies with cutting-edge technological innovation trends, laying a solid foundation for the overseas business development of innovative products in the future.
Following closely behind, from October 28th to 30th, Ab&B Bio-Tech Co., Ltd. once again participated in the CPHI 2025 Europe held in Frankfurt, Germany. This top-level event in the global pharmaceutical industry has attracted over 3000 companies from more than 120 countries and regions to participate.
In this exhibition, the company focused on promoting overseas markets, with a particular emphasis on core products such as subunit influenza vaccines and multi-level cooperative businesses. During the exhibition, the team accurately connected with customers from emerging markets such as Morocco, Pakistan, and Mexico, and conducted in-depth negotiations on topics such as product procurement, regional agency, and technical cooperation, fully demonstrating the product competitiveness and cooperation sincerity of Ab&B Bio-Tech Co., Ltd..
The successful participation in two international exhibitions is not only a concentrated display of Ab&B Bio-Tech Co., Ltd.'s technological strength and brand image, but also a crucial step for our overseas expansion.
At present, the company has established a graded follow-up list of potential customers based on valuable clues obtained from the exhibition, ensuring that all cooperation details are carried out in an orderly manner.
 |
 |
In the future, Ab&B Bio-Tech Co., Ltd. will fully utilize the market insights gained from this event, optimize product and service solutions in a targeted manner, develop precise research pipelines, and steadily promote the globalization of the enterprise
Relevant information
-
Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session.On August 5, 2026, a delegation comprising leaders and experts from the Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio-Tech CO.,LTD.JS to conduct an on-site inspection and hold a symposium. During the meeting, both parties engaged in in-depth discussions on topics such as innovative vaccine R&D, clinical evaluation, joint construction of technical platforms, sharing of data resources, talent cultivation, and technology commercialization, thereby accelerating the transition of their strategic cooperation from "paper-based consensus" to "substantive implementation." - The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
